(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Tuesday said it had completed a fundraise, conditional on admission, of GBP335,000 through a placing with Hybridan LLP, and announced a retail offer from Winterflood retail access platform to raise a maximum of GPB150,000. Read More
(Alliance News) - Physiomics PLC on Wednesday said it will collaborate with the University of Sheffield on research into an insect model of cancer treatment. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
Physiomics PLC - London-based oncology consultancy, which uses mathematical models to support the development of cancer treatment regimens and personalised medicine solutions - Gets a further contract from existing client Bicycle Therapeutics relating to an undisclosed programme. Expects this to be completed in Physiomics's current financial year. Read More
(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More
(Alliance News) - Physiomics PLC on Friday said Christophe Chassagnole's job title has changed from chief operating officer to chief scientific officer. Read More
(Alliance News) - Physiomics PLC on Wednesday said it entered into a further contract with its existing client Cancer Research UK to conduct analyses of a blood cancer treatment. Read More
(Alliance News) - Physiomics PLC on Monday hailed new opportunities in the emerging personalised dosing space, following the completion of its Partner study. Read More
Physiomics PLC - Oncology consultancy based in Oxford, England - Says it has been awarded a further contract by existing client Ankyra Therapeutics. The contract builds on work announced in March, and is expected to complete in the first quarter of 2023. Read More
